Press release
Inherited Retinal Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Featuring Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics
Inherited Retinal Disease Market
Therapies for Inherited Retinal Disease, including LUXTURNA, GS030, EA-2353, ADX-2191, and others, are anticipated to drive growth in the Inherited Retinal Disease Market in the coming years.
DelveInsight has released a comprehensive report titled "Inherited Retinal Disease - Market Insights, Epidemiology, and Market Forecast-2034," offering detailed insights into the historical and projected epidemiology of Inherited Retinal Disease, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Inherited Retinal Disease market report [https://www.delveinsight.com/report-store/inherited-retinal-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Some of the key facts of the Inherited Retinal Disease Market Report:
*
The Inherited Retinal Disease (IRD) market is projected to see steady growth with a consistent compound annual growth rate (CAGR) from 2024 to 2034. This growth is primarily driven by an increase in genetic mutations and a rising number of diagnosed cases. While no cure currently exists for IRDs, advancements in genetics and genomics, collaborative research, clinical trials, technological innovations, and precision medicine are fueling ongoing drug development and therapeutic options.
*
The current IRD market features limited competition, with only a few companies, including Novartis and Spark Therapeutics, offering approved treatments. In emerging markets, growth is expected to be slower due to restricted access to therapies. Most existing treatments manage IRD-related complications rather than addressing the root cause.
*
Looking ahead, companies such as Endogena Therapeutics, Aldeyra Therapeutics, and GenSight Biologics are progressing their therapies through mid- to late-stage development. With expected approvals during the forecast period (2024-2034), the IRD therapeutic market is anticipated to expand significantly with a strong CAGR.
*
Epidemiological data indicate that choroideremia affects approximately 1 in 50,000 individuals of European descent, while retinitis pigmentosa (RP) impacts about 1 in 4,000 to 8,000 people in Japan. The prevalence and epidemiology of IRDs are expected to evolve between 2020 and 2034.
*
In March 2025, the FDA approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals, marking the first and only treatment for Macular Telangiectasia type 2 (MacTel) and highlighting regulatory support for innovative therapies in rare retinal diseases.
*
Key IRD companies such as Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics, and others are actively developing new treatments to enhance the IRD therapeutic landscape. Promising pipeline therapies include LUXTURNA, GS030, EA-2353, ADX-2191, and others.
Inherited Retinal Disease Overview
Inherited retinal diseases (IRDs) comprise a clinically and genetically diverse group of disorders characterized by the degeneration or dysfunction of photoreceptor cells in the retina. These conditions often cause progressive vision loss, with symptoms that can emerge anytime from birth through late adulthood.
IRDs arise from mutations or defects in one or more genes, leading to impaired retinal cell function and gradual deterioration of vision. To date, around 250 genes have been linked to IRDs, though additional causative genes are likely yet to be discovered.
Typical symptoms include difficulty seeing in dim or dark conditions, loss of peripheral (side) vision which may result in collisions with objects or people, sensitivity to glare, and challenges in adapting to bright light.
Several forms of IRDs have been identified, with the most common being Retinitis Pigmentosa (RP), Choroideremia, Stargardt Disease, Cone-Rod Dystrophy, and Leber Congenital Amaurosis.
Inherited Retinal Disease Market Outlook
The main objectives in treating inherited retinal diseases (IRDs) are to alleviate symptoms, enhance patients' quality of life, and potentially slow disease progression. While a definitive cure is not yet available, supportive care, management of complications, and ongoing research aim to improve overall well-being for those affected.
Treatment approaches depend on the specific IRD and may include corrective lenses to improve vision, tints or filters to manage light sensitivity, or surgical procedures to repair retinal damage-particularly in advanced cases like X-linked retinoschisis or severe myopia-related complications.
In December 2017, the U.S. Food and Drug Administration (FDA) approved LUXTURNA (voretigene neparvovec-rzyl), a gene therapy for children and adults with inherited vision loss that can lead to blindness. This represented the first FDA-approved gene therapy targeting a disease caused by mutations in a single gene.
With ongoing research and innovation, there is optimism for more effective treatments and, ultimately, potential cures for IRDs. DelveInsight projects that the IRD market across the seven major markets (7MM) will experience significant growth and transformation between 2020 and 2034.
Discover how the Inherited Retinal Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/inherited-retinal-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Inherited Retinal Disease Marketed Drugs
*
LUXTURNA: Spark Therapeutics/Novartis
Inherited Retinal Disease Emerging Drugs
*
GS030: GenSight Biologics
*
EA-2353: Endogena Therapeutics
*
ADX-2191: Aldeyra Therapeutics
Scope of the Inherited Retinal Disease Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Inherited Retinal Disease Companies: Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics, and others
*
Inherited Retinal Disease Therapeutic Assessment: Inherited Retinal Disease current marketed and Inherited Retinal Disease emerging therapies
*
Inherited Retinal Disease Market Dynamics: Inherited Retinal Disease market drivers and Inherited Retinal Disease market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Inherited Retinal Disease Unmet Needs, KOL's views, Analyst's views, Inherited Retinal Disease Market Access and Reimbursement
To know what's more in our Inherited Retinal Disease report, visit https://www.delveinsight.com/report-store/inherited-retinal-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Inherited Retinal Disease Market Report:
*
Inherited Retinal Disease market report covers a descriptive overview and comprehensive insight of the Inherited Retinal Disease Epidemiology and Inherited Retinal Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
*
The Inherited Retinal Disease market report provides insights into the current and emerging therapies.
*
The Inherited Retinal Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Inherited Retinal Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Inherited Retinal Disease market.
Got queries? Click here to know more about the Inherited Retinal Disease market Landscape [https://www.delveinsight.com/sample-request/inherited-retinal-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Inherited Retinal Disease Patient Share (%) Overview at a Glance
5. Inherited Retinal Disease Market Overview at a Glance
6. Inherited Retinal Disease Disease Background and Overview
7. Inherited Retinal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Inherited Retinal Disease
9. Inherited Retinal Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Inherited Retinal Disease Emerging Therapies
12. Inherited Retinal Disease Market Outlook
13. Country-Wise Inherited Retinal Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Inherited Retinal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Inherited Retinal Disease Market Outlook 2034 [https://www.delveinsight.com/report-store/inherited-retinal-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Inherited Retinal Disease Pipeline Insights, DelveInsight
"Inherited Retinal Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inherited Retinal Disease market. A detailed picture of the Inherited Retinal Disease pipeline landscape is provided, which includes the disease overview and Inherited Retinal Disease treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=inherited-retinal-disease-market-epidemiology-therapies-companies-delveinsight-featuring-novartis-spark-therapeutics-endogena-therapeutics-aldeyra-therapeutics-gensight-biologics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inherited Retinal Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Featuring Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics here
News-ID: 4198424 • Views: …
More Releases from ABNewswire
Tay-Sachs Disease Pipeline 2025: Pioneering Clinical Developments by 4+ Global L …
DelveInsight's, "Tay-Sachs Disease - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Tay-Sachs Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Tay-Sachs Disease continues to impact populations worldwide and is…
Metachromatic Leukodystrophy Pipeline 2025: Pioneering Clinical Developments by …
DelveInsight's, "Metachromatic Leukodystrophy - Pipeline Insight, 2025," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Metachromatic Leukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Metachromatic Leukodystrophy (MLD) increasingly affecting populations worldwide and contributing…
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies - DelveInsight | F …
GM1 Gangliosidosis is a rare lysosomal storage disorder with an incidence of 1 in 100,000-200,000 live births, classified into infantile (0-6 months), late infantile (7 months-5 years), and adult-onset (6+ years) forms based on age at onset.
Therapies for GM1 Gangliosidosis, including PBGM01 and others, are expected to drive growth in the GM1 Gangliosidosis market over the coming years.
DelveInsight has released a new report titled "GM1 Gangliosidosis - Market Insights, Epidemiology,…
Re:Public: The Platform That Could End Political Yard Signs Forever
Orlando, FL - September 25, 2025 - Re:Public [https://republic.us/?utm_source=OtterPressRelease&utm_medium=August21&utm_campaign=Re%3APublic%3AThePlatformThatCouldEndPoliticalYardSignsForever], the community engagement platform revolutionizing how candidates connect with voters, will soon unveil a disruptive new feature: Candidate Profile Pages. Political campaigns waste millions every year on yard signs, mailers, and gimmicks that voters barely notice. For an annual subscription that is less than the cost of ten yard signs, every candidate - from local town council challengers to state and…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
